srpt gene therapy - Search News

Order byBest matchMost fresh

FDA Shuts Down Sarepta Gene Therapy Trials

SRPT Down After Third Death in Muscular Dystrophy Gene Therapy Program

Shares of Sarepta Therapeutics SRPT nosedived 35.9% on Friday following the death of a patient dosed with one of its experimental gene therapies. The company confirmed that a 51-year-old, non-ambulant (unable to walk) limb-girdle muscular dystrophy (LGMD) patient died due to acute liver failure (ALF).

· 1d

FDA Places Sarepta's Investigational Gene-Therapy Trials on Hold Following Patient Death

MyChesCo on MSN · 23h

FDA Shuts Down Sarepta Gene Therapy Trials After Three Deaths Linked to Liver Failure

Children's Hospital LA Pauses Use of Sarepta Gene Therapy

Digest more

· 11h · on MSN

Sarepta to pause Elevidys gene therapy shipments in U.S.

The U.S. Food and Drug Administration on Friday asked Sarepta to voluntarily stop shipments of the treatment linked to two deaths, but the company declined to do so.

· 3h

SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny

· 4h

Sarepta falls after gene therapy maker pauses Elevidys shipments in US

· 4h

Sarepta Faces Fresh Setback. Why Now’s Not the Time to Buy the Stock.

Sarepta Therapeutics was falling again in premarket trading Tuesday as its future looks increasingly shaky after it agreed to halt shipments of its Elevidys drug under pressure from the Food and Drug ...

STAT · 8h

In surprise reversal, Sarepta Therapeutics says it will pause shipments of Duchenne gene therapy

STAT · 1d

Pharmalittle: We’re reading about Sarepta resisting FDA over Elevidys, agency naming top drug regulator, and more

Sarepta Therapeutics: Why Is SRPT Stock Crashing?

The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.

Fintel on MSN17h

Mizuho Downgrades Sarepta Therapeutics (SRPT)

Fintel reports that on July 21, 2025, Mizuho downgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from Outperform to Neutral. Analyst Price Forecast Suggests 274.14% Upside As of July 17,